Portugal - English - HMA (Heads of Medicines Agencies)

lohmann animal health & co. - salmonella enteritidis 100000000 iu/ml - oral lyophilisate - chicken food - salmonella

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - salmon pancreas disease virus (spdv) strain f93-125 - emulsion for injection - unknown - pancreatic disease virus vaccine - fish - (atlantic) salmon - immunological - inactivated vaccine

Singapore - English - HSA (Health Sciences Authority)

zuellig pharma pte. ltd. - salmon-calcitonin synthetic - injection - 100 iu/ml - salmon-calcitonin synthetic 100 iu/ml

Singapore - English - HSA (Health Sciences Authority)

zuellig pharma pte. ltd. - salmon-calcitonin synthetic - injection - 50 iu/ml - salmon-calcitonin synthetic 50 iu/ml

Singapore - English - HSA (Health Sciences Authority)

aenon pharmaceuticals sea pte. ltd. - salmonella typhi (ty 21a berna strain) - capsule - not less than 2 x 10^9 viable organisms - salmonella typhi (ty 21a berna strain) not less than 2 x 10^9 viable organisms

United Kingdom - English - VMD (Veterinary Medicines Directorate)

lohmann animal health gmbh - salmonella enteritidis - lyophilisate for suspension - live bacterial vaccine - chickens

United Kingdom - English - VMD (Veterinary Medicines Directorate)

lohmann animal health gmbh - salmonella typhimurium - oral lyophilisate - live bacterial vaccine - chickens

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

apvma permit - salmonella enterica - vaccine

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim vetmedica gmbh - inactivated salmonella enteritidis pt4; inactivated salmonella typhimurium dt 104 - emulsion for injection - . - salmonella - chickens - immunological - inactivated vaccine

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon 2200 [iu] in 1 ml - fortical® calcitonin-salmon (rdna origin) nasal spray is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause with low bone mass relative to healthy premenopausal women. use of fortical® calcitonin-salmon (rdna origin) nasal spray is recommended in conjunction with an adequate calcium (at least 1000 mg elemental calcium per day) and vitamin d (400 international units per day) intake to retard the progressive loss of bone mass. the evidence of efficacy for calcitonin-salmon is based on increases in spinal bone mineral density (bmd) observed in clinical trials. two randomized, placebo-controlled trials were conducted in 325 postmenopausal women (227 treated with calcitonin-salmon nasal spray and 98 treated with placebo) with spinal, forearm or femoral bmd at least one standard deviation below the normal value for healthy premenopausal women. these studies conducted over two years demonstrated that 200 international units daily of calcitonin-salmon nasal spray